Description
TitleIntrinsic and viral regulation of the innate immune receptor RIG-I
Date Created2022
Other Date2022-10 (degree)
Extent1 online resource (141 pages) : illustrations
DescriptionRetinoic acid inducible gene I (RIG-I) is a helicase and innate immune receptor that recognizes viral 5’ triphosphorylated (5’PPP), blunt-ended dsRNAs. RIG-I activation stimulates the production of Type I interferons and cytokines that establish a cellular antiviral state and trigger the adaptive immune system. Due to the potent immune response from RIG-I activation, it is imperative that RIG-I remains autoinhibited in the absence of foreign RNA; recognition of self-RNAs, which are cytoplasmically abundant, leads to autoimmunity. The mRNA 5’ cap, a common self-RNA motif, combines the presence of an inverted G-cap and 2’-O ribose methylation to evade RIG-I recognition. Recently, RNAs capped with noncanonical moieties like NAD⁺, rather than the canonical G-cap, have been identified; however, it is unknown whether these non-canonically capped RNAs would activate RIG-I. Viruses have mechanisms to inactivate and evade RIG-I signaling, including influenza B virus nonstructural protein 1 (NS1B), whose expression leads to downregulation of RIG-I signaling. However, the exact mechanism by which the RNA-binding NS1B protein downregulates RIG-I signaling was unknown. My thesis addressed the following three questions: What intrinsic mechanisms prevent RIG-I from binding self RNA? Does RIG-I recognize the non-canonical capped dsRNAs? Does the influenza virus NS1B have RNA specificity and does it compete with RIG-I for RNA binding?
The signaling domains in RIG-I are connected to the helicase domain through a ~50 amino acids linker (CARD2-Hel1 linker or CHL), which is intrinsically disordered and negatively charged. Such regions often have regulatory functions; hence, I set out to understand the role of CHL using an array of biophysical, biochemical, and cellular assays with a panel of self and nonself-RNAs. My studies demonstrated that the CHL is responsible for three functions essential for RIG-I regulation. First, the CHL stabilizes the autoinhibitory CARD2:Hel2i interface known to enhance RIG-I’s RNA discriminatory ability by sequestering the signaling CARDs. Second, the CHL utilizes its negative charge to compete with incoming RNAs for the nonspecific helicase domain, ensuring C-terminal domain’s (CTD) fidelity for 5’PPP RNA. Third, the CHL destabilizes the RIG-I:RNA binding complex through an unidentified mechanism. This work was the first description of the CHL's role during intrinsic RIG-I regulation and thus is the first to recognize this linker as a crucial regulatory domain.
While it is well-understood that RIG-I discriminates against the host mRNA cap, recently, a new class of RNA caps has been identified in various organisms, including humans. Metabolites, such as NAD⁺ and FAD, can be used as the initiating nucleotide during transcription. The resulting RNA has a capped structure independent of the normal mRNA capping enzymes. These caps have not been identified with the same critical 2’-O ribose methylation in the mRNA cap that contributes to RIG-I evasion. I demonstrated using biochemical and cell-based assays that RIG-I binds to these alternatively capped RNAs with similar affinities as the 5’ PPP RNAs. The capped RNAs also stimulated the RIG-I signaling pathway comparable to the 5’PPP RNA. Thus, my work has discovered a new class of immunogenic RNAs that can be functionalized and leveraged in RIG-I based therapeutics. Non-canonical capped RNAs are found in bacteria, fungi, and mitochondria, and it remains to be determined whether RIG-I recognizing these non-viral RNAs is important for host immune function.
Influenza B virus, like all viruses, has multiple avenues to evade or down-regulate the host immune system. One such method is viral NS1 protein, which inhibits the RIG-I signaling pathway. NS1 of influenza B (NS1B) has a novel RNA binding domain in its C-terminal domain (CTD) which is not found in the closely related NS1 of influenza A. Using biophysical, biochemical, and cell-based assays and demonstrated that NS1B-CTD specifically recognizes blunt-ended, 5’ PPP dsRNA, RNA which potently activates RIG-I. The segmented influenza viral panhandle genomes also contain 5’PPP dsRNA ends. My work suggests that NS1 can specifically bind to these ends, obscuring viral genomic RNA from RIG-I recognition.
NotePh.D.
NoteIncludes bibliographical references
Genretheses
LanguageEnglish
CollectionSchool of Graduate Studies Electronic Theses and Dissertations
Organization NameRutgers, The State University of New Jersey
RightsThe author owns the copyright to this work.
Statistical Profile